1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Alzheimer's Disease Programs Initiative (ADPI) - Dementia Capable Community Health Worker Programs is sponsored by Administration for Community Living, Administration on Aging, U.S. Department of Health and Human Services. This program aims to strengthen dementia-capable community health worker programs within the National Aging Network and increase the number of people living with dementia who receive dementia-capable early detection, care navigation, and services.
Get alerted about grants like this
Get emailed when new opportunities from “Administration for Community Living, Administration on Aging, U.S. Department of Health and Human Services” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
ACL Announces Funding Opportunity for Dementia-Capable Community Health Worker Programs | ACL Administration for Community Living ACL Announces Funding Opportunity for Dementia-Capable Community Health Worker Programs ACL Announces Funding Opportunity for Dementia-Capable Community Health Worker Programs Applications due Wednesday, July 30, 2025 ACL has released the 2025 funding opportunity, "Alzheimer's Disease Programs Initiative (ADPI) - Developing Dementia-Capable Community Health Worker Programs in the National Aging Network."
Cooperative agreement grants awarded under this opportunity will support the development and expansion of dementia-capable community health worker (CHW) programs embedded in local area agencies on aging or state units on aging operating as a single planning and service area. CHWs work to improve conditions for health in communities with the highest rates of disease, disability, and death.
ADPI supports dementia-capable home and community-based services for people living with dementia and their caregivers. As a result of this initiative, ACL seeks to strengthen relationships with rural and underserved communities and address barriers to care for people living with dementia and their caregivers. An informational call for prospective applicants will be held on Wednesday, July 9, 2025, from 1:00-1:45 p.
m. ET. For security reasons, the passcode and the leader’s name will be required to join your call: Phone Number: 877-716-4291 A recording will be available soon after the call concludes at the following toll-free number: 866-490-2538.
See Notice of Funding Opportunity: HHS-2025-ACL-AOA-ADPI-0012, "Alzheimer's Disease Programs Initiative (ADPI) - Developing Dementia-Capable Community Health Worker Programs in the National Aging Network program," posted June 30, 2025. Last modified on 07/08/2025
According to the current listing, eligibility includes: Nationwide. Specific eligibility may vary per funding opportunity announcement. Confirm the full requirements in the official notice before applying.
The published deadline was August 3, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Alzheimer's Disease Programs Initiative (ADPI) - Dementia Capable Community Health Worker Programs is funded by Administration for Community Living, Administration on Aging, U.S. Department of Health and Human Services. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read articleARPA-H awarded $144M across 7 research teams to run the first clinical trials treating aging as a condition — not a disease. How PROSPR reshapes longevity funding and what grant seekers in biotech, academia, and health tech should know.
Read articleSeven research teams, five clinical trials, and a radical bet that aging can be slowed with existing drugs. A deep analysis of ARPA-H PROSPR and its implications.
Read article